Monograph Details
|
|
Ob/Gyn
> Menopause and HRT
|
|
VAGIFEM |
| Manufacturer |
|
Novo Nordisk |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Estrogen. |
| Generic Name |
|
Estradiol (as hemihydrate) 25micrograms; vaginal tabs. |
| Indications |
|
Atrophic vaginitis. |
| Children |
|
Not recommended. |
| Adults |
|
1 tab intravaginally once daily for 2 weeks, then 1 tab twice weekly. Reevaluate periodically. |
| Contraindications |
|
Breast or estrogen-dependent carcinoma. Undiagnosed abnormal vaginal bleeding. Thromboembolic disorders. Thrombophlebitis. Porphyria. Pregnancy (Cat.X). |
| Precautions |
|
Endometrial hyperplasia. Gallbladder disease. Do initial complete physical and repeat annually (include BP, mammogram, Pap smear). Severely atrophic vaginal mucosa or other trauma risk. Familial hyperlipoproteinemia. Discontinue 2 weeks before surgery associated with thromboembolism. See literature. |
| Adverse Reactions |
|
See literature. Increased risk of gallbladder disease, thromboembolic disorders. Spotting, discharge, rash, genital pruritus. |
| How Supplied |
|
Vaginal tabs—15 (w. applicators) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
